Cardiac implantable electronic device carriers undergoing transcatheter tricuspid valve annuloplasty: real-world insights
Clinical Research in Cardiology · 2025-07 · 114 (7) · 878-891
DOI: 10.1007/s00392-025-02616-5 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Research in Cardiology, online erschienen am 10.03.2025. Verfasst von Jan M Wrobel und 18 weiteren Autor:innen. Beteiligte Einrichtung: Heart Center, Department III of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50…. Hauptthemen laut MEDLINE: Tricuspid Valve Insufficiency, Tricuspid Valve, Cardiac Valve Annuloplasty, Cardiac Catheterization. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Abbott Vascular, Edwards Lifesciences, JenaValve.
Abstract (Originalsprache)
Background
Transtricuspid cardiac implantable electronic devices (CIEDs) complicate the management of tricuspid regurgitation (TR). Transcatheter tricuspid valve annuloplasty (TTVA) offers a promising approach due to minimal interaction with leaflets and transvalvular CIEDs, though real-world evidence is limited.
Methods
This bi-center, retrospective study includes 204 consecutive patients who underwent TTVA with the Cardioband (Edwards Lifesciences) for severe symptomatic TR. Patients were divided into CIED carriers and non-CIED carriers. CIED carriers were further classified into those with lead-associated TR (LTR-A) and those with TR unrelated to CIED leads (LTR-B).
Results
Among the 204 patients, 41 (20%) were CIED carriers. Of these, 24% had mixed TR etiology (functional and LTR-A), while 76% had predominantly functional TR (LTR-B). Compared to non-CIED-carriers, CIED carriers were more symptomatic (NYHA-FC > II; 93% vs. 89%; p = 0.026) with comparable TR severity at baseline. Intraprocedural success according to the Tricuspid Valve Academic Research Consortium was 68% in CIED carriers and 70% in non-CIED carriers ( p = 0.851). LTR-A was associated with poorer TR reduction immediately after TTVA ( p = 0.022). Overall safety was comparable, with right ventricular lead dislodgement occurring in one patient. Beyond that, CIED function remained unimpaired. At 30 days, echocardiographic follow-up showed comparable TR reduction (TR ≤ II: 56% vs. 68%; p = 0.219) and NYHA-FU ≤ II (63% vs. 70%; p = 0.524) in CIED-and non-CIED carriers, respectively.
Conclusions
TTVA achieves significant TR reduction, providing a safe and effective therapeutic option for TR treatment in CIED carriers. What is known? TTVA using the Cardioband has been approved for severe, symptomatic TR patients, however data on the safety and efficacy in CIED carriers is lacking. What the study adds? Intraprocedural success and safety were comparable in CIED and non-CIED carriers treated with TTVA. Subgroup analyses showed a trend towards worse outcome and efficiency of TTVA in patients with LTR-A. Postinterventional CIED interrogations did not show critical technical issues. Graphical abstract Intraprocedural success and TR reduction following TTVA in CIED- and non-CIED-carriers. Blue arrows indicate CIED lead trajectory through tricuspid valve. BL Baseline, FU = 30-day Follow Up, LTR-A Lead-associated Tricuspid Regurgitation, type A, LTR-B Lead-associated Tricuspid Regurgitation, type B, TR Tricuspid Regurgitation, TTVA Transcatheter Tricuspid Valve Annuloplasty
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Heart Center, Department III of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany.
- Clinic for General and Interventional Cardiology/Angiology, Herz- Und Diabeteszentrum NRW, Ruhr-Universität Bochum, Med. Fakultät OWL (Universität Bielefeld), Bad Oeynhausen, Germany.
- Heart Center, Department III of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany. maria.koerber@uk-koeln.de.
Förderung
- Abbott Vascular
- Edwards Lifesciences
- JenaValve
- Universitätsklinikum Köln
Zitieren
APA
Wrobel, J. M., Kirchner, J., Friedrichs, K., Gietzen, T., Althoff, J., Hasse, C., von Stein, P., Wörmann, J., von Stein, J., Curio, J., Rudolph, F., Ivannikova, M., Iliadis, C., Steven, D., Baldus, S., Rudolph, V., Pfister, R., Gerçek, M., & Koerber, M. I. (2025). Cardiac implantable electronic device carriers undergoing transcatheter tricuspid valve annuloplasty: real-world insights. Clinical Research in Cardiology, 114(7), 878-891. https://doi.org/10.1007/s00392-025-02616-5
Vancouver
Wrobel JM, Kirchner J, Friedrichs K, Gietzen T, Althoff J, Hasse C, et al. Cardiac implantable electronic device carriers undergoing transcatheter tricuspid valve annuloplasty: real-world insights. Clinical Research in Cardiology. 2025;114(7):878-891. doi:10.1007/s00392-025-02616-5
BibTeX
@article{Wrobel2025,
author = {Wrobel, Jan M and Kirchner, Johannes and Friedrichs, Kai and Gietzen, Thorsten and Althoff, Jan and Hasse, Caroline and von Stein, Philipp and Wörmann, Jonas and von Stein, Jennifer and Curio, Jonathan and Rudolph, Felix and Ivannikova, Maria and Iliadis, Christos and Steven, Daniel and Baldus, Stephan and Rudolph, Volker and Pfister, Roman and Gerçek, Muhammed and Koerber, Maria I},
title = {Cardiac implantable electronic device carriers undergoing transcatheter tricuspid valve annuloplasty: real-world insights},
journal = {Clinical Research in Cardiology},
year = {2025},
volume = {114},
number = {7},
pages = {878--891},
doi = {10.1007/s00392-025-02616-5}
}
EUVIMED